All In Biotech

NDA 213973 · Deciphera Pharms

Qinlock

Ripretinib · Oral · Kinase Inhibitor

NovelBreakthrough therapyPriority reviewOrphan

Last checked: Nov 19, 2026Latest source record: May 6, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2020

May 15, 2020

Approved uses

1

Original approval plus efficacy supplements

Registered trials

12

3 Phase 3, 0 recruiting

FAERS reports

5,243

2,276 serious, 497 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect May 12, 2025.

QINLOCK is indicated for the treatment of adult patients with advanced gastrointestinal stromal tumor (GIST) who have received prior treatment with 3 or more kinase inhibitors, including imatinib. QINLOCK is a kinase inhibitor indicated for the treatment of adult patients with advanced gastrointestinal stromal tumor (GIST) who have received prior treatment with 3 or more kinase inhibitors, including imatinib. ( 1 )

Mechanism: Ripretinib is a tyrosine kinase inhibitor that inhibits KIT proto-oncogene receptor tyrosine kinase (KIT) and platelet derived growth factor receptor A (PDGFRA) kinase, including wild type, primary, and secondary mutations. Ripretinib also inhibits other kinases in vitro, such as PDGFRB, TIE2, VEGFR2, and BRAF.

Therapeutic areas: Oncology · Ophthalmology

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • May 15, 2020 Original approval · Type 1 - New Molecular Entity · priority review NovelBreakthrough therapyOrphanLabelLetterReview
1 products under this application
  • QINLOCK · RIPRETINIB 50MG · TABLET, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Ripretinib" as an intervention, any sponsor and status, largest first.

All 12 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • fatigue688
  • alopecia594
  • death381
  • underdose374
  • extra dose administered357
  • nausea338
  • drug ineffective334
  • hospitalisation319
  • disease progression298
  • pain295
  • constipation292
  • diarrhoea279

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2020303
2021727
2022833
2023951
2024842
20251,016
2026571

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Qinlock (Ripretinib)

2024 spending

$78.7M

Beneficiaries

352

1,814 claims

Per beneficiary

$223,478

$454.81 per unit

View as table
YearSpending
2020$16,379,736
2021$36,976,955
2022$44,753,132
2023$52,132,977
2024$78,664,212

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 23 on PubMed

Sponsor: Deciphera Pharms

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.